5-氟尿嘧啶化疗耐药的研究进展  

Chemotherapy resistance of 5-fluorouracil:research advances

作　　者：丁欣[1] 陈国江 DING Xin CHEN Guo-jiang(Department of Immunology, Institute of Basic Medical Sciences, Academy of Military Medical Sciences, Beijing 100850, China)

机构地区：[1]北京军事医学科学院基础医学研究所,北京100850

出　　处：《国际药学研究杂志》2017年第6期491-494,共4页Journal of International Pharmaceutical Research

基　　金：国家重点基础研究发展计划(973计划)资助项目(2015CB553704);国家自然科学基金资助项目(81472647;81672803)

摘　　要：5-氟尿嘧啶(5-FU)自1957年问世以来,已被广泛应用于胃肠、头、颈、胸和卵巢等部位恶性肿瘤的治疗。作为嘧啶类似物,5-FU通过抑制胸苷酸合成酶并将其代谢产物整合到DNA和RNA中发挥抗癌作用。5-FU单药或联合用药虽至今仍用于胃肠道恶性肿瘤的一线治疗,但因患者易对其产生耐药性而使总体有效率降低。5-FU化疗耐药可能源自于酶的异常、基因异常和肿瘤微环境异常等因素。本文对5-FU作用机制及其化疗耐药机制的研究进展做一综述。5-Fluorouracil（5-FU）has been widely used to treat gastrointestinal,head,neck,chest and ovarian malignant tumors since 1957. As an analogue of pyrimidine,5-FU plays anti-cancer roles by inhibiting thymioylate synthase and integrating its metabolites into DNA and RNA. Although 5-FU is one of the first-line therapeutic compounds for gastrointestinal malignant tumor as a single drug or in combination with other drugs,its effectiveness is hindered by its low efficiency,which may be due to chemotherapy resistance. 5-FU chemotherapy resistance may stem from enzyme abnormality,genetic abnormality and tumor microenvironment. In this paper,we make a review about 5-FU actions and the mechanisms underlying chemotherapy resistance.

关 键 词：5-氟尿嘧啶 化疗耐药 胸苷酸合成酶 

分 类 号：R979.1[医药卫生—药品]